Clinical trial

Systemic Corticosteroids Avoidance Study in Severe Asthma Patients

NCT03629249

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2018-12-13

PhasePHASE3

Study timeline

Study start (actual)2018-12-13Date precision: day

Registry last updated2021-10-11

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Asthmaunresolved

Interventions

Placebo once dailyDRUG

QAW039 150 mg once dailyDRUG

QAW039 450 mg once dailyDRUG

Sponsors & collaborators

Novartis Pharmaceuticalslead sponsor

Mapped research locations

BerlinGermany6 Buenos AiresArgentina5 Saint PetersburgRussia4 MoscowRussia3 LeipzigGermany3 HamburgGermany2 FrankfurtGermany2 BogotáColombia2 DallasTexas, United States1 MadridSpain1 The BronxNew York, United States1 SofiaBulgaria1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03629249 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.